Novartis AG ADR (NVS)vsOwlet Inc (OWLT)
NVS
Novartis AG ADR
$145.39
-2.00%
HEALTHCARE · Cap: $275.95B
OWLT
Owlet Inc
$4.86
-6.54%
HEALTHCARE · Cap: $142.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 53423% more annual revenue ($56.58B vs $105.71M). NVS leads profitability with a 23.9% profit margin vs -37.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OWLT
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$145.39
$35.44 premium
Margin of Safety
+30.6%
Fair Value
$15.80
Current Price
$4.86
$10.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 29.6% year-over-year
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -802.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : OWLT
The strongest argument for OWLT centers on Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while OWLT is a growth play — different risk/reward profiles.
OWLT carries more volatility with a beta of 1.83 — expect wider price swings.
OWLT is growing revenue faster at 29.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 32/100), backed by strong 23.9% margins. OWLT offers better value entry with a 30.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a leading innovator in infant health technology, focused on enhancing the safety and well-being of newborns through state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to deliver real-time data on infants' heart rates and oxygen levels directly to parents’ mobile devices, empowering them with critical health insights. As the demand for pediatric health monitoring grows, Owlet is strategically positioned to broaden its product portfolio and solidify its standing in the dynamic infant health market. By emphasizing actionable data and improving pediatric care, Owlet is establishing a robust foothold at the intersection of healthcare and technology, appealing to institutional investors keen on innovative health solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?